Conduit Pharmaceuticals Stock Revenue
| CDTTW Stock | 0.01 0.00 0.00% |
Conduit Pharmaceuticals fundamentals help investors to digest information that contributes to Conduit Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Conduit Stock. The fundamental analysis module provides a way to measure Conduit Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Conduit Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 2.5 B | 2.6 B |
Conduit | Revenue |
Conduit Pharmaceuticals Company Revenue Analysis
Conduit Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Conduit Pharmaceuticals Revenue | 2.46 B |
Most of Conduit Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Conduit Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Conduit Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Conduit Pharmaceuticals is extremely important. It helps to project a fair market value of Conduit Stock properly, considering its historical fundamentals such as Revenue. Since Conduit Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Conduit Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Conduit Pharmaceuticals' interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Conduit Pharmaceuticals reported 2.46 B of revenue. This is 67.73% lower than that of the Biotechnology sector and 231.26% higher than that of the Health Care industry. The revenue for all United States stocks is 73.92% higher than that of the company.
Conduit Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Conduit Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Conduit Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Conduit Pharmaceuticals by comparing valuation metrics of similar companies.Conduit Pharmaceuticals is currently under evaluation in revenue category among its peers.
Conduit Fundamentals
| Return On Asset | -1.09 | ||||
| Number Of Shares Shorted | 1.35 K | ||||
| Revenue | 2.46 B | ||||
| EBITDA | 266.46 M | ||||
| Net Income | 198.41 M | ||||
| Total Debt | 1.23 B | ||||
| Book Value Per Share | (9.50) X | ||||
| Cash Flow From Operations | 344.8 M | ||||
| Beta | 2.27 | ||||
| Total Asset | 3.26 B | ||||
| Retained Earnings | 1.18 B | ||||
| Working Capital | 3.93 M | ||||
| Net Asset | 3.26 B |
About Conduit Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Conduit Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Conduit Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Conduit Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.